Roche licenses Rona Therapeutics’ ALK7-targeting RNAi obesity drug candidate in deal worth up to $1.16 billion
Roche entered an exclusive worldwide license deal with Rona Therapeutics for an investigational ALK7-targeting RNAi obesity therapy. Rona will receive up to $100 million in upfront and near-term milestone payments, with additional milestones of up to $1.06 billion and tiered royalties on global net sales.
1. License deal terms
Roche entered an exclusive worldwide license deal with Rona Therapeutics for an investigational ALK7-targeting RNAi therapy for obesity. Rona will receive up to $100 million in upfront and near-term milestone payments; additional development, regulatory and commercial milestones could reach $1.06 billion, with tiered royalties on global net sales.
